同种主动脉瓣衰败后再次换瓣:外科手术与经导管介入的比较
两组5年生存率相当,无严重瓣周漏。
要点
- TAVR组ICU 1天 vs SAVR组2天(P<0.001),住院10.5天 vs 13天(P=0.028)。
- 两组5年生存率相当,均无严重瓣周漏;TAVR组瓣膜中位尺寸26mm vs SAVR组23mm。
核心结论
- 同种主动脉瓣结构衰败后行SAVR结果可接受,但围术期风险仍较高且难以预测。
- TAVR是合理且更易获得的替代方案,短期和中期结果良好;在无相关禁忌证时,TAVR是目前本中心首选治疗。
研究设计与样本
- 回顾性比较研究,纳入1993至2022年81例既往接受同种主动脉瓣后因衰败需再次换瓣的患者。
主要发现
- SAVR组中79%可行孤立SAVR,21%需行根部手术;TAVR组79%经股动脉、21%经心尖入路。
- 瓣膜中位尺寸:SAVR组23(22.3-23.2)mm vs TAVR组26(25.2-26.9)mm。
- 延长通气:TAVR组0% vs SAVR组21%(P=0.013);ICU时间:TAVR组1天 vs SAVR组2天(P<0.001);住院时间:TAVR组10.5天 vs SAVR组13天(P=0.028)。
- 两组5年生存率统计学可比,未观察到严重瓣周漏。
临床怎么用
- 对于同种主动脉瓣衰败需再次换瓣的患者,TAVR可作为开放手术的替代方案,短期和中期结果良好。
- 在无相关禁忌证时,TAVR是目前该中心的首选治疗选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Aortic valved allografts (homografts) have been used alternatively to mechanical or biological valve prostheses in expectation of better durability; however, homograft valves do degenerate, and redo procedures have proven challenging due to heavy wall calcification. The aim of the study was to compare the outcome of open surgical (SAVR) and transcatheter aortic valve replacement (TAVR) in degenerated homografts. METHODS: Between 1993 and 2022, 81 patients underwent repeat aortic valve procedures having previously received an aortic homograft. The redo had become necessary due to regurgitation in 85% and stenosis in 15%. Sixty-five percent underwent open surgery, 35% TAVR. RESULTS: Isolated SAVR was possible in 79%, and root procedures were necessary in 21%. TAVR was performed in 79% via transfemoral and 21% via transapical access. Median prosthetic valve size was 23 (22.3-23.2) mm in the SAVR and 26 (25.2-26.9) in the TAVR group. Thirty-day mortality was 0% in the TAVR and 7% in the SAVR group (P = n.s.). TAVR showed a significantly better outcome concerning prolonged ventilation (0 vs 21%, P = 0.013) as well as ICU (1 vs 2 days; P < 0.001) and in-hospital stay (10.5 vs 13 days; P = 0.028). Five-year survival was statistically comparable between groups, and no severe leakage was observed. CONCLUSIONS: SAVR following structural homograft degeneration shows acceptable results, but the perioperative risk remains substantial and poorly predictable. TAVR presents a reasonable and more easily accessible alternative and is associated with good short- and mid-term results. In the absence of relevant contraindications, TAVR is presently the preferred treatment option for these patients at our center.
引用
- Peterss S, Fabry TG, Steffen J, et al. Aortic valved homograft degeneration: surgical or transcatheter approach for repeat aortic valve replacement? Eur J Cardiothorac Surg. 2024. PMID: 39037934. doi:10.1093/ejcts/ezae280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。